1月13日盘中科创板股天智航-U涨停，截至13:56，股价报22.67元，成交8.44亿元，换手率9.02%，振幅 21.12%。 融资融券数据显示，该股最新（1月12日）两融余额为2.12亿元，其中，融资余额为2.12亿元，较上一个 交易日增加34.62万元，增幅为0.16%；融券余额为14.36万元，较上一个交易日减少1.09万元，降幅为 7.05%。近10日两融余额合计增加2168.83万元，增幅为11.40%，其间融资余额增长11.40%，融券余额增 长10.57%。（数据宝） （文章来源：证券时报网） 科创板个股中，截至发稿上涨的共有239只，涨幅在10%以上的共有11只，涨幅较高的有天智航-U、近 岸蛋白、光云科技等，分别上涨20.01%、19.99%、19.98%，下跌的有356只，跌幅较大的有航天环宇、 江航装备、国科军工，分别下跌12.94%、12.72%、10.98%。 资金面上，天智航-U上一交易日主力资金净流入1270.74万元，近5日净流出2134.01万元。 ...

Group 1 - Weiteou signed a strategic cooperation agreement with Qiteng Robotics to focus on safety upgrades in high-risk industries, leveraging new materials and robotics [1] - Dongfang Caifu's subsidiary received approval from the CSRC to issue subordinate bonds totaling up to 20 billion yuan [2] - Haibo Zhongke's controlling shareholder plans to reduce holdings by up to 2.98% of the company's shares [3] Group 2 - Shengyang Technology's subsidiary FTA is expanding into the foreign satellite internet terminal business, which is still in the early commercialization stage [4] - Cangge Mining expects a net profit increase of 43.41%-53.1% for 2025, projecting a profit of 3.7-3.95 billion yuan [5] - Jinlongyu plans to invest approximately 1.2 billion yuan to build a production line for solid-state batteries with an annual capacity of 2 GWh [6] Group 3 - Shengda Resources intends to acquire a 55% stake in Guangxi Laibin Jinshi Mining for 269.5 million yuan [7] - Zhifei Biological's CA111 injection has entered Phase I clinical trials, targeting diabetes and weight loss treatment [8] - Qusleep Technology's specific shareholders plan to reduce their holdings by up to 2.58% of the company's shares [9] Group 4 - Innovation Medical's subsidiary has a product expected to generate revenue of 114,000 yuan in 2025 [11] - Blue Ocean Cursor noted that AI-driven revenue currently constitutes a small portion of overall revenue [12] - *ST Yanshi anticipates a loss for the 2025 fiscal year, with revenue expected to be below 300 million yuan [13] Group 5 - ST Yishite will lift risk warnings and change its stock name, resuming trading on January 14 [14] - Shaoyang Hydraulic clarified that its products do not directly serve commercial aerospace clients [15] - Boss Electric plans to invest 100 million yuan in Youte Smart Kitchen to deepen strategic cooperation [16] Group 6 - Guo An Da's controlling shareholder plans to reduce holdings by up to 3% of the company's shares [17] - *ST Mingjia has lifted the delisting risk warning following the completion of its restructuring plan [18] - Haixiang Pharmaceutical signed an innovative drug cooperation agreement with Wanbangde Pharmaceutical [19] Group 7 - Palm Holdings plans to transfer stakes in two project companies for debt compensation, amounting to 258 million yuan [20] - Bohai Leasing's subsidiary Avolon is projected to have a fleet of 1,132 aircraft by the end of 2025 [21] - Zhenyou Technology reported that satellite internet revenue accounted for approximately 7.15% of total revenue in the first three quarters of 2025 [22] Group 8 - Blue Arrow Electronics intends to acquire at least 51% of Chengdu Xinyi Technology [23] - Shunhao Co. stated that its investment in Tianshu Chuangxin will have a minimal impact on its 2025 performance [24][25] - Baichuan Co.'s deputy general manager plans to reduce holdings by up to 0.65% of the company's shares [26] Group 9 - Zhewen Interconnect reported that its GEO business has not yet formed a mature profit model [27] - XW Communication's controlling shareholder plans to reduce holdings by up to 1% of the company's shares [28] - Electric Science Digital indicated that its satellite communication products are not its main business [29] Group 10 - Bojun Technology expects a net profit increase of 35%-65% for 2025, projecting a profit of 828-1,012 million yuan [30] - Rongchang Bio signed a licensing agreement for the RC148 drug with AbbVie, with an initial payment of 650 million USD [31] - Guoxin Technology's state investment fund plans to reduce holdings by up to 2.37% of the company's shares [32] Group 11 - Hengxuan Technology's controlling shareholder plans to reduce holdings by up to 3% of the company's shares [33][34] - *ST Chengchang announced a stock suspension for investigation due to abnormal trading [35] - Zhongji Xuchuang's subsidiary plans to issue warrants to incentivize its core team [36] Group 12 - Zhuoshengwei expects a net loss of 255-295 million yuan for 2025 [37] - Pingtan Development anticipates a loss for the 2025 fiscal year [38] - Nanjing Bank's major shareholder increased its stake by 123.472 million shares [39] Group 13 - Jingao Technology expects a net loss of 4.5-4.8 billion yuan for 2025 [40] - Mingyang Smart plans to acquire control of Dehua Company, with stock suspension [41] - Vanadium Titanium Co. anticipates a loss for the 2025 fiscal year [42][43] Group 14 - Tianzhihang announced a delay in its "Smart Medical Center Construction Project" [44]

Core Viewpoint - The company announced a delay in the "Smart Medical Center Construction Project" while maintaining the original investment purpose, total investment amount, and implementation entity, ensuring no substantial adverse impact on the project [1][4][7]. Fundraising Overview - The company raised a total of RMB 370,199,990.23 by issuing 29,545,091 shares at a price of RMB 12.53 per share, with a net amount of RMB 359,756,594.00 after deducting underwriting fees [1][3]. - The funds are managed in a dedicated account as per regulations to protect investor rights [2]. Project Status and Delay Reasons - The project is focused on three main areas: remote collaboration platform construction, operational platform upgrades, and data-based analysis applications [5]. - The delay is attributed to objective factors such as industry cyclical fluctuations and regulatory policy adjustments, which have slowed down procurement decisions and project approvals in the downstream hospital sector [6]. - The company has adjusted its investment pace to ensure project quality and efficiency, postponing the project completion date to December 2027 [6][7]. Approval Process - The board of directors approved the project delay on January 9, 2026, and the sponsor, CITIC Securities, provided a no-objection opinion, indicating that no shareholder meeting was required for this decision [8][9].

中信建投证券股份有限公司 关于北京天智航医疗科技股份有限公司 部分募投项目延期的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐人"）作 为北京天智航医疗科技股份有限公司（以下简称"天智航"或"公司"）2021 年 度向特定对象发行 A 股股票的保荐人，根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》和《科创板上市公司持续监管办法（试行）》等 有关规定，对天智航部分募投项目延期事项进行了审慎核查，核查情况及核查意 见如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意北京天智航医疗科技股份有限公司向 特定对象发行股票注册的批复》（证监许可[2022]797 号）同意注册，公司向特定 对象发行 A 股股票 29,545,091 股，每股面值人民币 1 元，每股发行价格 12.53 元， 募集资金总额为 370,199,990.23 元。扣除中信建投证券承销及保荐费用合计人民 币 6,500,000.00 元后的募集资金为 363,699,990.23 元，已由中信建投证券于 2023 年 ...

证券代码：688277 证券简称：天智航 公告编号：2026-002 北京天智航医疗科技股份有限公司 关于部分募投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京天智航医疗科技股份有限公司（以下简称"天智航"或"公司"）于 2026 年 1 月 9 日召开了第六届董事会第二十七次会议审议通过了《关于部分募投项目 延期的议案》，同意公司对向特定对象发行股票募集资金投资项目"智慧医疗中 心建设项目"达到预定可使用状态日期进行调整。 本次募投项目延期未改变募集资金投资用途、投资总额和实施主体，不会对 募投项目的实施造成实质性不利影响。保荐人中信建投证券股份有限公司（以下 简称"中信建投证券"或"保荐人"）对该事项出具了明确无异议的核查意见， 该事项无需提交公司股东会审议。现将有关情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意北京天智航医疗科技股份有限公司向 特定对象发行股票注册的批复》（证监许可[2022]797 号）同意注册，公司向特定 对象发行 A 股股票 29,545,091 ...

Group 1 - Tianzhihang Medical Technology Co., Ltd. focuses on the research, production, sales, and service of orthopedic surgical navigation robots, with a revenue composition of 58.31% from navigation robots, 23.86% from supporting equipment and consumables, 16.49% from technical services, and 1.31% from other sources [1] - As of January 12, Tianzhihang's stock price increased by 5.46% to 18.94 CNY per share, with a total market capitalization of 8.636 billion CNY and a trading volume of 9.9702 million CNY [1] Group 2 - Huaxia Fund's Huaxia CSI Robot ETF (562500) increased its holdings in Tianzhihang by 1.6284 million shares in the third quarter, bringing its total holdings to 8.7238 million shares, which represents 1.93% of the circulating shares [2] - The Huaxia CSI Robot ETF has a total asset size of 22.798 billion CNY and has achieved a year-to-date return of 4.35%, ranking 2512 out of 5579 in its category [2] Group 3 - The fund manager of Huaxia CSI Robot ETF is Hualong, who has been in the position for 3 years and 145 days, with the fund's total asset size at 35.957 billion CNY and a best return of 139.26% during the tenure [3]

南方财经1月9日电，天智航(688277.SH)公告，持股5%以上股东先进制造产业投资基金及其一致行动人 京津冀产业协同发展投资基金于2025年12月9日至2026年1月8日期间，通过集中竞价和大宗交易方式合 计减持公司股份4,653,729股，占公司总股本的1.02%。其中，先进制造基金减持2,321,381股，持股比例 由3.48%下降至2.97%；京津冀基金减持2,332,348股，持股比例由3.48%下降至2.97%。本次权益变动 后，两基金合计持股比例由6.95%降至5.93%。 ...

证券代码：688277 证券简称：天智航 公告编号：2026-001 北京天智航医疗科技股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的提示性公告 先进制造产业投资基金（有限合伙）及其一致行动人京津冀产业协同发 展投资基金（有限合伙）保证向本公司提供的信息真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一 致。 1.身份类别 | | □控股股东/实际控制人及其一致行动人 | | --- | --- | | 投资者及其一致 | ☑其他 5%以上大股东及其一致行动人 | | 行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用于无控股股 | | | 东、实际控制人） | | | □其他______________ | 2.信息披露义务人信息 信息披露义务人名称 投资者身份 统一社会信用代码 先进制造产业投资基 金（有限合伙） □ 控股股东/实控人 □ 控股股东/实控人的 一致行动人 ☑ 其他直接持股股东 ☑ 91310000342453915W □ 不适用 京津冀产业协同发展 投资基金（有限合伙） □ 控股股东/实控人 □ ...

天智航公告称，截至2026年1月8日收盘，先进制造产业投资基金（有限合伙）及其一致行动人京津冀产 业协同发展投资基金（有限合伙）持股比例由6.95%降至5.93%，权益变动触及1%整数倍。2025年12月9 日至2026年1月8日，先进制造基金减持232.14万股，占总股本0.51%；京津冀基金减持233.23万股，占 比0.51%。目前，减持计划尚未实施完毕。 ...

Group 1 - The core viewpoint of the news highlights a strong performance in the medical device sector, particularly with the medical device ETF (159883) showing significant gains and attracting substantial capital inflow [1][4] - The medical device index (H30217) rose by 1.81%, with notable individual stock performances such as Kewei Medical (301087) increasing over 17% and Shuoshi Bio (688399) rising over 12% [1][3] - The medical device ETF has seen a net inflow of 9.32 billion yuan over the past three days, with a peak single-day inflow of 517 million yuan, indicating strong investor interest [1][4] Group 2 - Kewei Medical has made strategic investments in the brain-computer interface sector, including a 5.83% stake in Nulingke Medical, which focuses on implantable brain-computer interface technology [3][4] - The domestic brain-computer interface sector is experiencing significant growth, with a recent unicorn company completing approximately 2 billion yuan in financing, marking it as the second-largest financing in the field globally [4] - The medical device ETF (159883) is the largest in the market, with over 23% exposure to brain-computer interface stocks, and is expected to benefit from domestic innovation and technological advancements [4][5]